Metabolic disorders and chronic viral disease: The case of HIV and HCV

[Guest guest]

Diabetes Metab. 2008 Nov 28. [Epub ahead of print]

Metabolic disorders and chronic viral disease: The case of HIV and HCV.

Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S.

Service des maladies infectieuses, hôpital Tenon, AP-HP, 4, rue de la Chine,

75970 Paris cedex 20, France.

The importance of metabolic disorders in the pathophysiology of human

immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections is becoming

increasingly apparent. Metabolic anomalies, with their potential for

multiple-organ involvement, are to be expected, given the chronic nature of

these diseases, and the intracellular dysregulation associated with them. Not

only have the endocrine and cytokine metabolic anomalies seen in HIV and HCV

infections been linked with the metabolic syndrome, but they also appear to have

some pathways in common. Studying the differences and similarities between these

metabolic anomalies may add to our understanding of HIV and HCV infection, and

provide guidance on how to treat these chronic diseases. This review highlights

the principal underlying factors for metabolic disorders in these chronic viral

diseases-namely insulin resistance and liver damage. Both the chronic viral

state itself and the host immune response give rise to glucose and lipid

metabolic disorders that, in turn, are risk factors for hepatic damage. The

various interactions between HIV and/or HCV with insulin resistance, type 2

diabetes, steatosis and fibrogenesis should be considered when determining the

treatment and long-term follow-up of patients. Recent data indicate that HCV

clearance improves insulin resistance and hepatic function in HCV-infected

patients treated with interferon with or without ribavirin.

PMID: 19046914 [PubMed - as supplied by publisher]

[Guest guest]

Diabetes Metab. 2008 Nov 28. [Epub ahead of print]

Metabolic disorders and chronic viral disease: The case of HIV and HCV.

Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S.

Service des maladies infectieuses, hôpital Tenon, AP-HP, 4, rue de la Chine,

75970 Paris cedex 20, France.

The importance of metabolic disorders in the pathophysiology of human

immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections is becoming

increasingly apparent. Metabolic anomalies, with their potential for

multiple-organ involvement, are to be expected, given the chronic nature of

these diseases, and the intracellular dysregulation associated with them. Not

only have the endocrine and cytokine metabolic anomalies seen in HIV and HCV

infections been linked with the metabolic syndrome, but they also appear to have

some pathways in common. Studying the differences and similarities between these

metabolic anomalies may add to our understanding of HIV and HCV infection, and

provide guidance on how to treat these chronic diseases. This review highlights

the principal underlying factors for metabolic disorders in these chronic viral

diseases-namely insulin resistance and liver damage. Both the chronic viral

state itself and the host immune response give rise to glucose and lipid

metabolic disorders that, in turn, are risk factors for hepatic damage. The

various interactions between HIV and/or HCV with insulin resistance, type 2

diabetes, steatosis and fibrogenesis should be considered when determining the

treatment and long-term follow-up of patients. Recent data indicate that HCV

clearance improves insulin resistance and hepatic function in HCV-infected

patients treated with interferon with or without ribavirin.

PMID: 19046914 [PubMed - as supplied by publisher]